Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.72M | 2.22M | 9.91M | 275.40K | 4.40M |
| Gross Profit | -2.72M | -2.22M | -9.91M | -275.40K | -4.40M |
| SG&A Expenses | 2.37M | 2.15M | 2.14M | 1.84M | 3.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.09M | 4.37M | 3.33M | 4.46M | 8.18M |
| Operating Income | -5.09M | -4.37M | -3.33M | -4.46M | -8.18M |
| Income Before Tax | -5.67M | -4.43M | -3.26M | -4.47M | -8.14M |
| Income Tax Expenses | 141.20K | 100.50K | 504.70K | 11.00K | 1.20K |
| Earnings from Continuing Operations | -5.81M | -4.53M | -3.77M | -4.49M | -8.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.81M | -4.53M | -3.77M | -4.49M | -8.14M |
| EBIT | -5.09M | -4.37M | -3.33M | -4.46M | -8.18M |
| EBITDA | -5.09M | -4.36M | -3.32M | -4.45M | -8.18M |
| EPS Basic | -0.19 | -0.16 | -0.14 | -0.17 | -0.42 |
| Normalized Basic EPS | -0.12 | -0.10 | -0.07 | -0.11 | -0.26 |
| EPS Diluted | -0.19 | -0.16 | -0.14 | -0.17 | -0.42 |
| Normalized Diluted EPS | -0.12 | -0.10 | -0.07 | -0.11 | -0.26 |
| Average Basic Shares Outstanding | 30.34M | 28.69M | 27.71M | 26.53M | 19.22M |
| Average Diluted Shares Outstanding | 30.34M | 28.69M | 27.71M | 26.53M | 19.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |